Pyrazolyl-substituted heteroaryls and their use as medicaments
US-9845314-B2 · Dec 19, 2017 · US
Heteroaryl SYK inhibitors
US10947243B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10947243-B2 |
| Application number | US-201916535337-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 8, 2019 |
| Priority date | Mar 19, 2014 |
| Publication date | Mar 16, 2021 |
| Grant date | Mar 16, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to new substituted heteroaryls of formula 1 wherein A is selected from the group consisting of N and CH D is selected from the group consisting of CH, N, NH, S and O, E is selected from the group consisting of C and N, T is selected from the group consisting of C and N, G is selected from the group consisting of C and N, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R 1 , M and R 3 are defined according to claim 1 , and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating pulmonary arterial hypertension comprising the step of administering to a person in need thereof a compound of the following formula: or a pharmaceutically acceptable salt thereof. 2. A method of treating comprising the step of administering to a person in need thereof a compound of the following formula: or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
containing three or more hetero rings · CPC title
condensed with carbocyclic rings, e.g. benzimidazoles · CPC title
of the kidneys · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
for bone diseases, e.g. rachitism, Paget's disease · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10947243B2 cover?
- The invention relates to new substituted heteroaryls of formula 1 wherein A is selected from the group consisting of N and CH D is selected from the group consisting of CH, N, NH, S and O, E is selected from the group consisting of C and N, T is selected from the group consisting of C and N, G is selected from the group consisting of C and N, and wherei…
- Who is the assignee on this patent?
- Boehringer Ingelheim Int
- What technology area does this patent fall under?
- Primary CPC classification A61K31/416. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).